Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization study of iodine-131-labeled metuximab injection plus TACE for hepatocellular carcinoma
ChiCTR-TRC-11001556Phase 4Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2011
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, open-label trial of licofelone and iodine-131 metuximab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Time to progression and Overall survival. Started May 2011; status: completed.
02
Drugs
licofeloneiodine-131 metuximab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001556.